Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal

References

• Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5–18.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Adler CH, Charles D, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015;349(1–2):84–93. .
   PubMed Web of Science ®Google Scholar
• Simpson DM, Hallett M, Ashman EJ. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86(19):1–9.
   Web of Science ®Google Scholar
• Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131–1138.
   PubMed Web of Science ®Google Scholar
• Restani L, Antonucci F, Gianfranceschi L, et al. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci. 2011;31(44):15650–15659. .
   PubMed Web of Science ®Google Scholar
• Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist. 2015;21(1):44–61.
   PubMed Web of Science ®Google Scholar
• Weise D, Weise CM, Naumann M. Central effects of botulinum neurotoxin-Evidence from human studies. Toxins (Basel). 2019;11(1):21.
   PubMedGoogle Scholar
• Poewe W, Burbaud P, Castelnovo G, et al. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial. Mov Disord. 2016;31(11):1649–1657.
   PubMed Web of Science ®Google Scholar
• Comella C, Ferreira JJ, Pain E, et al. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol. 2020;268(3):903–912.
   PubMed Web of Science ®Google Scholar
• Colosimo C, Charles D, Misra VP, et al. INTEREST IN CD2 study group. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: findings from a prospective, observational study. J Neurol Sci. 2020;416:117015.
   PubMed Web of Science ®Google Scholar
• Ritter JM. Drug regulation & therapeutic efficacy. Br J Clin Pharmacol. 2008;65(6):801–802.
   PubMed Web of Science ®Google Scholar
• Consky E, Lang A. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York, NY: Marcel Dekker Inc; 1994. p. 211–237.
   Google Scholar
• Jost WH, Hefter H, Stenner A, et al. Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. J Neural Transm. 2013;120(3):487–496.
   PubMed Web of Science ®Google Scholar
• Clinical Review Report: AbobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada, Inc.): Indication: To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017, Appendix 5, Validity of Outcome Measures. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535053
   Google Scholar
• Dashtipour K, Mari Z, Jankovic J, et al. Minimal clinically important change in patients with cervical dystonia: results from the CD PROBE study. J Neurol Sci. 2019;405:116413.
   PubMed Web of Science ®Google Scholar
• Chen Q, Vu JP, Cisneros E, et al. Postural directionality and head tremor in cervical dystonia. Tremor Other Hyperkinet Mov. 2020;10: DOI:10.7916/tohm.v0.745.
   PubMed Web of Science ®Google Scholar
• Comella CL, Perlmutter JS, Jinnah HA, et al. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016;31(4):563–569.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Rivest J, Stell R, et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med. 1992;85(9):524–529.
   PubMed Web of Science ®Google Scholar
• Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46(4):1066–1072. PMID: 8780093.
   PubMed Web of Science ®Google Scholar
• Wissel J, Kanovsky P, Ruzicka E, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol. 2001;248(12):1073–1078.
   PubMed Web of Science ®Google Scholar
• Cullis PA, O’Brien CF, Truong DD, et al. Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. Adv Neurol. 1998;78:227–230.
   PubMedGoogle Scholar
• Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439–1446.
   PubMed Web of Science ®Google Scholar
• Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431–1438.
   PubMed Web of Science ®Google Scholar
• Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000;55:29–35.
   Web of Science ®Google Scholar
• Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1–2):103–109.
   PubMed Web of Science ®Google Scholar
• Dressler D, Tacik P, Adib Saberi F. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)). J Neural Transm. 2014;121(1):29–31.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Jankovic J, Holds JB, et al. Observational study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): interim results for the first 170 subjects with Blepharospasm. Tremor Other Hyperkinet Mov. 2014;4:238.
   PubMedGoogle Scholar
• Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases. J Rehabil Med. 2015;47(2):183–186.
   PubMed Web of Science ®Google Scholar
• Han Y, Stevens AL, Dashtipour K, et al. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol. 2016;263(4):772–780.
   PubMed Web of Science ®Google Scholar
• Duarte GS, Castelão M, Rodrigues FB, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;10:CD004314.
   PubMedGoogle Scholar
• Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;5:CD004315.
   Google Scholar
• Rodrigues FB, Duarte GS, Marques RE, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2020;11:CD003633.
   PubMedGoogle Scholar
• Dressler D, Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev Neurother. 2017;17(5):487–494.
   PubMed Web of Science ®Google Scholar
• Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res. 2012;22(4):265–273.
   PubMed Web of Science ®Google Scholar
• Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5(2):249–266.
   PubMed Web of Science ®Google Scholar
• Mejia N, Vuong K, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20(5):592–597.
   PubMed Web of Science ®Google Scholar
• Hsiung GYR, Das SK, Ranawaya R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002;17(6):1288–1293. .
   PubMed Web of Science ®Google Scholar
• Brashear A, Bergan K, Wojcieszek J, et al. Patients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin Type A. Mov Disord. 2000;15(1):150–153. .
   PubMed Web of Science ®Google Scholar
• Skogseid I, Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol. 2005;12(3):163–170.
   PubMed Web of Science ®Google Scholar
• Brin MF, Comella CL, Jankovic J. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353–1360.
   PubMed Web of Science ®Google Scholar
• Fasano A, Paramanandam V, Jog M. Use of abobotulinumtoxinA in adults with cervical dystonia: a systematic literature review. Toxins (Basel). 2020;12(8):470.
   Web of Science ®Google Scholar
• Haussermann P, Marczoch S, Klinger C, et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord. 2004;19(3):303–308. .
   PubMed Web of Science ®Google Scholar
• Berman B, Seeberger L, Kumar R. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord. 2005;20(2):233–237.
   PubMed Web of Science ®Google Scholar
• Mohammadi B, Buhr N, Bigalke H, et al. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res. 2009;31(5):463–466. .
   PubMed Web of Science ®Google Scholar
• Colosimo C, Charles D, Misra VP, et al. INTEREST IN CD2 study group. How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. J Neurol. 2019;266(12):3038–3046.
   PubMed Web of Science ®Google Scholar
• Jochim A, Meindl T, Mantel T, et al. Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. J Neurol. 2019;266(8):1879–1886.
   PubMed Web of Science ®Google Scholar
• Chinnapongse RB, Lew MF, Ferreira JJ, et al. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 2012;35:215–223.
   Google Scholar
• Bentivoglio AR, Di Stasio E, Mulas D, et al. Long- Term Abobotulinumtoxin a treatment of cervical dystonia. Neurotox Res. 2017;32(2):291–300.
   PubMed Web of Science ®Google Scholar
• Kessler K, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol. 1999;246(4):265–274.
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58(1):1–7.
   PubMed Web of Science ®Google Scholar
• Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13:11–15.
   PubMed Web of Science ®Google Scholar
• Kaymak B, Gürçay E, Ata AM, et al. Ultrasound imaging and guidance in the management of cervical dystonia: a caveat on the compartmentalization of sternocleidomastoid muscle. Parkinsonism Relat Disord. 2017;43:127–128.
   PubMed Web of Science ®Google Scholar
• Kaymak B, Kara M, Yağiz OA, et al. Innervation zone targeted botulinum toxin injections. Eur J Phys Rehabil Med. 2018;54(1):100–109.
   PubMed Web of Science ®Google Scholar
• Kaymak B, Kara M, Gürçay E, et al. Sonographic guide for botulinum toxin injections of the neck muscles in cervical dystonia. Phys Med Rehabil Clin N Am. 2018;29(1):105–123. PMID: 29173657.
   PubMed Web of Science ®Google Scholar
• Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019;11(9):491.
   Web of Science ®Google Scholar
• Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol. 1999;104(4):200–209.
   PubMed Web of Science ®Google Scholar
• Kuebbing SE, Reimer AP, Rosenthal SA, et al. Long-term research in ecology and evolution: a survey of challenges and opportunities. Ecol Monogr. 2018;88(2):245–258.
   Web of Science ®Google Scholar
• Jankovic J, Truong D, Patel AT, et al. Injectable DaxibotulinumtoxinA in Cervical dystonia: a Phase 2 Dose-Escalation multicenter study. Mov Disord Clin Pract. 2018;5(3):273–282.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Comella C, Hauser RA, et al. A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxina for injection in the treatment of cervical dystonia. Abstracts presented at TOXINS 2021
   Google Scholar
• Jinnah HA, Comella CL, Perlmutter J, et al. Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy? Toxicon. 2018;147:89–95.
   PubMed Web of Science ®Google Scholar
• Hefter H, Spiess C, Rosenthal D. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm. 2014;121(5):513–519.
   PubMed Web of Science ®Google Scholar
• Cordivari C, Misra VP, Vincent A, et al. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord. 2006;21(10):1737–1741. .
   PubMed Web of Science ®Google Scholar
• Jinnah HA, Goodmann E, Rosen AR, et al. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol. 2016;263(6):1188–1194. .
   PubMed Web of Science ®Google Scholar
• Nijmeijer SW, Koelman JH, Standaar TS, et al. Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord. 2013;19(5):533–538. .
   PubMed Web of Science ®Google Scholar
• Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48–e54.
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Moulyd S, Popoff MR, et al. Systematic analysis of botulinum neurotoxin type A immunogenicity in clinical studies. Basal Ganglia. 2017;9:12–17.
   Web of Science ®Google Scholar
• Walter U, Mühlenhoff C, Benecke R, et al. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. Neurology. 2020;94(20):e2109–e2120.
   PubMed Web of Science ®Google Scholar
• Patel N, Hanfelt J, Marsh L, et al. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014;85(8):882–884.
   PubMed Web of Science ®Google Scholar
• Cisneros E, Stebbins GT, Chen Q, et al. It’s tricky: rating alleviating maneuvers in cervical dystonia. J Neurol Sci. 2020;419:117205.
   PubMed Web of Science ®Google Scholar
• Jost WH, Tatu L, Pandey S, et al. Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col-Cap concept. J Neural Transm. 2020;127(1):45–50.
   PubMed Web of Science ®Google Scholar
• Tatu L, Jost W. Anatomy and cervical dystonia: “dysfunction follows form”. J Neural Transm. 2017;124(2):237–243.
   PubMed Web of Science ®Google Scholar
• Jost WH, Tatu L. Selection of muscles for botulinum toxin injections in cervical dystonia. Mov Disord Clin Pract. 2015;2(3):224–226.
   PubMed Web of Science ®Google Scholar
• Fheodoroff K, Bhidayasiri R, Jacinto J, et al. Ixcellence network: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. Funct Neurol. 2017;32(2):103–110. DOI: 10.11138/fneur/2017.32.2.103.
   PubMed Web of Science ®Google Scholar
• Chung TM, Jacinto LJ, Colosimo C, et al. Botulinum Neurotoxin-A injection in adult cervical dystonia and spastic paresis: results from the INPUT (injection practice, usage and training) survey. Front Neurol. 2020;11:570671.
   PubMed Web of Science ®Google Scholar
• Cools CI, De Vries NM, Bloem BR. Happiness: a novel outcome in parkinson studies? J Parkinsons Dis. 2020;10(3):1261–1266.
   PubMedGoogle Scholar
• Berman BD, Junker J, Shelton E, et al. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017;88(7):595–602.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Jankovic J, Marsh L, et al. Cervical dystonia and substance abuse. J Neurol. 2018;265(4):970–975.
   PubMed Web of Science ®Google Scholar
• Han V, Skorvanek M, Smit M, et al. Prevalence of non-motor symptoms and their association with quality of life in cervical dystonia. Acta Neurol Scand. 2020;142(6):613–622.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75–81. .
   PubMed Web of Science ®Google Scholar
• Vizcarra JA, Sánchez-Ferro Á, Maetzler W, et al. The Parkinson’s disease e-diary: developing a clinical and research tool for the digital age. Mov Disord. 2019;34(5):676–681.
   PubMed Web of Science ®Google Scholar
• Marsili L, Espay AJ, Merola A. Future of neurologic examination in clinical practice. JAMA Neurol. 2018;75(3):383.
   PubMed Web of Science ®Google Scholar